Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 318

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

Biomarkers of response to PD-1/PD-L1 inhibition

Open access
Maleki Vareki, Saman, Garrigós, Carmen, Duran, Ignacio·2017·Critical Reviews in Oncology/Hematology

Abstract

Immunotherapy is a promising treatment strategy for cancer that has recently shown unprecedented survival benefits in selected patients. A number of immunomodulatory agents that target immune system checkpoints such as the cytotoxic T-lymphocyte antigen 4 (CTLA-4), the programmed death-1 (PD-1) or its ligand (PD-L1), have received regulatory approval for the treatment of multiple cancers including malignant melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, and recurrent or metastatic head and neck squamous cell carcinoma. Nevertheless, a substantial proportion of patients treated with checkpoint inhibitors have little or no benefit while these treatments are costly and might have associated toxicities. Hence, the establishment of valid predictors of treatment response has become a priority. This review summarizes the current evidence around biomarkers of response to PD-1/PD-L1 inhibition, considering features related to the tumor and to the host immune system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2017.06.001

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Cited by

See all 318

Metadata

Authors
Maleki Vareki, S., Garrigós, C., & Duran, I.
Venue
Critical Reviews in Oncology/Hematology
Publisher
Elsevier BV
Published
2017-08
Volume
116
Pages
116-124
ISSN
1040-8428 (ISSN-L)
OpenAlex
W2621587943
Cited by
318
References
97
FWCI
15.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarkers of response to PD-1/PD-L1 inhibition. https://app.cochat.ai/papers/10.1016/j.critrevonc.2017.06.001
The paper
Maleki Vareki, S., Garrigós, C., & Duran, I. (2017). Biomarkers of response to PD-1/PD-L1 inhibition. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2017.06.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.